Search
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune
Synonyms: (T,G)-A-LAcamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783] … It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Synonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULINCategories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.
Micafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Products: MYCAMINE POWDER FOR SOLUTION FOR INFUSION 50MG/VIALSonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … [L56193,L56194] The application received priority review, breakthrough therapy designation, and orphan drug designation, and was reviewed under Project Orbis with the EMA as an official observer.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity. … [A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]
Synonyms: 13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-olMixtures: Cyred EQ, Cyred EQDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalIt is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Andexanet alfa
go.drugbank.com/drugs/DB14562ApprovedIt was developed by Portola Pharmaceuticals and was approved in in May 2018. … It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with [rivaroxaban] and [apixaban] in cases of life-threatening or uncontrolled
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. … [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.